aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
aTyr Pharma, Inc.NASDAQ: ATYR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $10.79M (cash outflow) fell 27.5% year over year, behind the +10.4% change in trailing-twelve-month net income. Sequentially, it fell 22.7% from the prior quarter. Over 3 fiscal years it compounded at +17.8% a year.
Context
- Net income amounted to 39012.1% of revenue in FY2025, up 11768.3 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$40.94M (-44.8%) for the fiscal year ending Dec 2026, a slowdown from the +15.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.79M-22.7% QoQ
- Last fiscal yearDec 2025
- -$74.12M+15.8% YoY
- LTMMar 2026
- -$70.03M+10.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.5% | -39.0% | -11.6 pp |
| 1 year | +15.8% | -44.8% | -60.5 pp |
| 3-year CAGR | +17.8% | -21.0% | -38.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (74.12M) USD
- Year-over-year change
- -15.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.12M) | -15.8% |
| FY2024 | 2024-12-31 | (64.02M) | -27.1% |
| FY2023 | 2023-12-31 | (50.39M) | -11.1% |
| FY2022 | 2022-12-31 | (45.34M) | -34.3% |
| FY2021 | 2021-12-31 | (33.77M) | — |
Net Income vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.4% is the 4th highest of 8, against a peer median of -7.7%.
- Net income amounts to 36859.5% of revenue for ATYR, versus a peer median of 96.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $88.87M USD | -31.7% | -6.3% | — | |
| LTM Mar 2026 | $86.3M USD | +66.7% | — | 2193.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M USD | -7.7% | +35.7% | — |
| LTM Mar 2026 | $70.03M USD | +10.4% | +17.8% | 36859.5% | |
| LTM Mar 2026 | $58.88M USD | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $43.6M USD | +98.3% | -25.7% | 96.7% | |
| LTM Mar 2026 | $39.95M USD | +162.9% | +13.7% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.18M CAD | -73.6% | +21.9% | 66.4% |
| Peer median (excluding ATYR) | — | -7.7% | +3.7% | 96.7% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.61M | 2.15M | 2.6M | 2.99M | 5M |
| Change in Working Capital | (2.59M) | (833K) | 15.01M | (6.92M) | 7.45M |
| Accounts Receivables | 1.6M | (11.92M) | 9.05M | 402K | 863K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 47K | 0 | 3.26M | (1.34M) | (33K) |
| Other Working Capital | (4.24M) | 11.09M | 2.7M | (5.98M) | 6.62M |
| Other Non-Cash Items | 363K | 441K | (3.19M) | (2.71M) | (1.87M) |
| Operating Cash Flow | (33.08M) | (41.89M) | (33.22M) | (69.12M) | (61.99M) |
| Capital Expenditures | (192K) | (1.64M) | (4.22M) | (65K) | (77K) |
| Acquisitions (Net) | 50K | 0 | 0 | 7K | 12K |
| Purchases of Investments | (126.51M) | (42.12M) | (106.98M) | (69.1M) | (93.45M) |
| Sales of Investments | 35.08M | 90.83M | 91.05M | 86.39M | 86.6M |
| Other Investing Activities | 0 | 179K | 15K | 0 | 1.85M |
| Investing Cash Flow | (91.57M) | 47.25M | (20.13M) | 17.23M | (5.05M) |
| Debt Repayment | 0 | (66K) | (394K) | (497K) | (539K) |
| Common Stock Issued | 109.95M | 5.47M | 66.52M | 40.26M | 66.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 73K | 45K | 105K | 100K | 0 |
| Financing Cash Flow | 110.03M | 5.45M | 66.23M | 39.86M | 66.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.62M) | 10.81M | 12.88M | (12.02M) | (1.03M) |
| Free Cash Flow | (33.27M) | (43.53M) | (37.44M) | (69.18M) | (62.06M) |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.